Clinical studies have demonstrated that Alvesco® is at least as effective as other inhaled corticosteroids (ICSs).1–3
Alvesco® has a fast onset of action and significantly decreases airway hyperresponsiveness after 2.5 hours of administration.4 It also has a prolonged duration of action, which allows for once-daily dosing. Desisobutyryl-ciclesonide (des-CIC) forms lipid conjugates in the lung,5 which, combined with the drug’s high lipophilicity, improves drug retention in the lung tissue.
Read on to find out how the clinical efficacy of Alvesco® compares with:
In this section, you can also find out how Alvesco® reduces inflammation in the small airways and improves small airway function.6–8
Thanks to high protein-binding and low oral bioavailability, Alvesco® minimizes systemic side effects.
Alvesco® has a specific pharmacological profile which enables it to target inflammation, whilst minimizing side effects.
Find out more about how to use the Alvesco® inhaler correctly.
Tell your colleagues about the benefits of Alvesco® by sharing this page to them.
© Takeda Pharmaceuticals International GmbH, Thurgauerstrasse 130, 8152 Glattpark-Opfikon, Zurich,